Home/Biosimilar Atlas/Companies/Teva

Teva

Biosimilar developer, Israel. 5 development products across 5 molecules: denosumab, filgrastim, follitropin alfa, ranibizumab, teriparatide.

First approval in the Atlas: Sep 2008, Ratiograstim, filgrastim (EMA)
FDAproducts approved1
EMAproducts approved3
MHRAproducts approved3
PMDAproducts approved0
HCproducts approved1
CDSCOproducts approved0
EDEproducts registered1
Connections
5molecules5products5 of 7markets0candidates in trials8companies on the same molecules

About Teva

Teva sells more biosimilars than it develops. Its own filgrastim was among the first growth factor biosimilars in Europe in 2008, its follitropin Ovaleap was the first of its kind in Europe, and its denosumab reached Europe and the United States in 2025 and 2026. It also sells Alvotech's adalimumab and ustekinumab in the United States and a ranibizumab in Canada.

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
DenosumabPonlimsi / Degevma TVB-009Mar 2026Nov 2025MHRA····3/7
FilgrastimTevagrastim / Ratiograstim XM02·Sep 2008····Jun 20222/7
Follitropin alfaOvaleap XM17·Sep 2013MHRA····2/7
RanibizumabRanopto····Oct 2023··1/7
TeriparatideTeriparatide Teva··MHRA····1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Teva, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

Intas PharmaceuticalsFive shared molecules: denosumab, filgrastim, follitropin alfa, ranibizumab, teriparatide12 molecules in its portfolioEnzene BiosciencesThree shared molecules: denosumab, ranibizumab, teriparatide6 molecules in its portfolioLupinThree shared molecules: denosumab, filgrastim, ranibizumab6 molecules in its portfolioReliance Life SciencesThree shared molecules: denosumab, follitropin alfa, ranibizumab14 molecules in its portfolioZydus LifesciencesThree shared molecules: follitropin alfa, ranibizumab, teriparatide11 molecules in its portfolioFuji PharmaTwo shared molecules: denosumab, filgrastim5 molecules in its portfolioGedeon RichterTwo shared molecules: denosumab, teriparatide4 molecules in its portfolioSamsung BioepisTwo shared molecules: denosumab, ranibizumab10 molecules in its portfolio

Chronology

Compare Teva with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.